Company Overview: TEVA

Upcoming Projects (TEVA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (TEVA)

Comparing Ingrezza to Austedo as treatments for Tardive Dyskinesia
Tickers: NBIX, TEVA
Executed On: May 05, 2025 at 04:30 PM EDT
Discussing the phase 2b RELIEVE UCCD study of Teva's anti-TL1A antibody, duvakitug, in ulcerative colitis and Crohn’s disease
Tickers: TEVA, SNY
Executed On: Feb 04, 2025 at 05:30 PM EST
A Second Discussion With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.
Tickers: CORT, TEVA
Executed On: Feb 02, 2024 at 04:00 PM EST
Speaking With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.
Tickers: CORT, TEVA
Executed On: Jan 30, 2024 at 04:30 PM EST
Legal Alpha: Understanding the patent strength of Catalyst Pharmaceuticals’ Firdapse after Teva’s ANDA challenge
Tickers: CPRX, TEVA
Executed On: Feb 07, 2023 at 02:00 PM EST

Expired Projects (TEVA)

Discussing the UC landscape and how upcoming new therapies could affect that
Tickers: ROIV, MORF, TEVA
Execute By: Oct 27, 2023
A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab
Tickers: ALDR, AMGN, TEVA, NVS
Execute By: May 17, 2017
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016

Upcoming & Overdue Catalysts (TEVA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (TEVA)

FDA approves Teva's (TEVA) generic Narcan nasal spray for opioid overdose
Ticker: TEVA
Occurred on: Apr 19, 2019
U.S. FDA Approval of AJOVY (fremanezumab-vfrm) Injection, Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults
Ticker: TEVA
Occurred on: Sep 14, 2018
FDA approves new dosage strength of Teva's (TEVA) buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Ticker: TEVA
Occurred on: Sep 07, 2018
Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients
Tickers: ALDR, TEVA, AMGN
Occurred on: Feb 26, 2018
TEVA's NDA for SD-809 in Tardive Dyskinesia Granted PDUFA Date of August 30th
Ticker: TEVA
Occurred on: Aug 30, 2017
Phase 2 data of TV-45070 for Postherpetic neuralgia due 1H 2017
Tickers: XENE, TEVA
Occurred on: Jun 27, 2017
Deleware Court Rules Actavis Labs' (TEVA) Abbreviated New Drug Application (ANDA) for Generic Version of Pain Med Zohydro ER Infringes on Two of Pernix' (PTX) Patents
Tickers: PTX, TEVA, Actavis Labs
Occurred on: Feb 23, 2017
Teva's Vantrela ER Approved by FDA for Pain Management
Ticker: TEVA
Occurred on: Jan 18, 2017
European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion of Teva's (TEVA) Trisenox in Treatment of Promyelocytic Leukemia. Final Decision Expected in ~60 Days.
Ticker: TEVA
Occurred on: Nov 21, 2016
Teva's Generic Version of Daiichi Sankyo's (DSNKY) Tribenzor Approved by FDA for Hypertension
Tickers: TEVA, DSNKY
Occurred on: Nov 07, 2016
U.S. Centers for Medicare & Medicaid Services (CMS) Establishes Specific Reimbursement Code for Teva and Eagle's (EGRX) BENDEKA, a Treatment for Chronic Lymphocytic Leukemia and Certain Patients with Indolent B-cell Non-Hodgkin Lymphoma
Tickers: TEVA, EGRX
Occurred on: Nov 02, 2016
Merrimack Pharma's (TEVA) Abbreviated New Drug Application (ANDA) for Generic Version of Janssen's (JNJ) Doxorubicin Accepted for Review by FDA
Tickers: TEVA, JNJ, Merrimack Pharmaceuticals
Occurred on: Oct 31, 2016
The FDA has asked Teva to re-analyze blood levels of certain metabolites in a CRL for SD-809 NDA. Teva will submit its response in Q3
Ticker: TEVA
Occurred on: Oct 20, 2016
FDA Places Hold on Teva (TEVA) and Regeneron's (REGN) Phase 2b Trial Evaluating Fasinumab in Chronic Low Back Pain
Tickers: TEVA, REGN
Occurred on: Oct 17, 2016
FDA Sends Warning Letter to Teva Regarding Deficiencies in Hungarian Manufacturing Site
Ticker: TEVA
Occurred on: Oct 14, 2016
Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Occurred on: Oct 12, 2016
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
Ticker: TEVA
Occurred on: Sep 22, 2016
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
Ticker: TEVA
Occurred on: Sep 19, 2016
Teva (TEVA) Launches Generic Version of Merck's CUBICIN for Complicated Skin and Bloodstream Infections in U.S
Tickers: MRK, TEVA
Occurred on: Sep 15, 2016
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE 40 mg
Ticker: TEVA
Occurred on: Aug 24, 2016
European Commission Grants Marketing Authorization for Teva’s CINQAERO (reslizumab)
Ticker: TEVA
Occurred on: Aug 18, 2016
Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
Tickers: TEVA, Actavis Generics
Occurred on: Jul 27, 2016
Teva Receives CHMP Positive Opinion for CINQAERO (reslizumab)
Ticker: TEVA
Occurred on: Jun 24, 2016
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta (Exenatide Injection) in the United States
Tickers: TEVA, AZN
Occurred on: Jun 23, 2016
TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States
Tickers: TEVA, ATRS
Occurred on: Jun 23, 2016
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology
Ticker: TEVA
Occurred on: Jun 07, 2016
Teva to complete phase 3 trial for SD-809 as a treatment for Chorea Associated With Huntington Disease in December 2015 (via Aspex acquisition)
Tickers: TEVA, ASPX
Occurred on: Apr 18, 2016
New business venture focused on generics in Japan to be established in or after April 2016; owned 51% by Teva and 49% by Takeda
Tickers: TEVA, TEVA.TA, TKPYY
Occurred on: Apr 01, 2016
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA (bendamustine hydrochloride) Injection
Tickers: TEVA, EGLT
Occurred on: Jan 28, 2016
TEVA Launches Generic Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States
Tickers: TEVA, TEVA.TA
Occurred on: Jan 05, 2016
Teva and Active Biotech discontine high doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients; CONCERTO and ARPEGGIO Trials Continue Study
Tickers: TEVA, TEVA.TA, ACTI.F
Occurred on: Jan 04, 2016
TEVA secures additional $658M in net proceeds from its equity offering via the full exercise of the underwriters over-allotment of 5.4M ADSs and 337.5K Mandatory Convertible Preferred Shares, increasing the company's take to $7.24B
Tickers: TEVA, TEVA.TA
Occurred on: Jan 03, 2016

Strategic Initiatives (TEVA)

Teva and Syqe Medical Sign Marketing Agreement for Medical Cannabis Inhaler
Tickers: TEVA, Syqe Medical
Announcement Date: Nov 28, 2016
Teva Expands Research Partnership with IBM to Develop Cognitive Computing Technologies to Enhance Drug Repurposing
Tickers: TEVA, IBM
Announcement Date: Oct 26, 2016
Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Announcement Date: Oct 12, 2016
Teva (TEVA) and South Korean Celltrion Enter into Exclusive Partnership to Commercialize Biosimilars to Rituxan and Herceptin in the U.S and Canada
Tickers: TEVA, Celltrion
Announcement Date: Oct 06, 2016
Teva (TEVA) Divests Actavis Generics Assets in UK and Ireland Through $766MM Sale to Intas Pharmaceuticals
Tickers: TEVA, Accord Healthcare Limited, Actavis Generics, Intas Pharmaceuticals
Announcement Date: Oct 05, 2016
Teva (TEVA) Launches Generic Epzicom in U.S for Combination Treatment of HIV-1 Infection
Ticker: TEVA
Announcement Date: Sep 28, 2016
Teva (TEVA) and Regeneron (REGN) Agree to Global Commercialization and Development Deal for REGN's Fasinumab in Chronic Lower Back Pain
Tickers: TEVA, REGN
Announcement Date: Sep 20, 2016
Teva Completes Acquisition of Actavis Generics
Tickers: TEVA, AGN
Announcement Date: Aug 02, 2016
Impax Signs Definitive Agreements to Acquire Generic Products
Tickers: IPXL, TEVA
Announcement Date: Jun 21, 2016
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
Tickers: TEVA, AbCellera
Announcement Date: Feb 02, 2016
Teva and Checkpoint Therapeutics Announce License Agreement in which Checkpoint will obtain the exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, CEP-9722, an oral poly (ADP-ribose) polymerase
Tickers: FBIO, TEVA
Announcement Date: Jan 07, 2016

TEVA Overview